ESG risk score -
Environmental score -
Social score -
Governance score -
ESG risk category -
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Oruka Therapeutics Inc.
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol ORKA:xnas
Currency USD
NASDAQ
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) 85.98%
1 year 619.92%
3 years 2761.42%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -2.32
Volatility (30 days) 100.88%
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Sector Healthcare
Industry -
Market cap 3bn
Data provided by /
/ Others were interested in
See all stocksFrequently asked questions
To buy Oruka Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Oruka Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Oruka Therapeutics Inc. is ORKA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Oruka Therapeutics Inc. has its primary listing on NASDAQ. You can trade Oruka Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Oruka Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Oruka Therapeutics Inc. as part of a broader investment portfolio.